Dermatology and wound-care specialist Crawford is considering a market float after the recent success of rival ConvaTec.
Crawford is looking “more closely” at an IPO, according to a report in the Sunday Telegraph, following ConvaTec’s listing last week.
Shares in the company have climbed by some 10 per cent after coming to market on 26 October. ConvaTec is one of Crawford’s biggest competitors.
It has been a tough year for London’s IPO market, with the UK’s vote to quit the European Union prompting some to shy away from offerings.
In October Crawford posted a 19 per cent rise in half-year sales to £13m, driven by growth in the UK, Germany and the US, while revenues from the company’s North American subsidiary more than doubled.
Crawford is currently awaiting regulatory approval for an anti-infective dressing in the US, expected in the new year.